ZeClinics

🚨 @ECHA investigates new method potentially replacing toxicity testing with fish! The Agency has contracted the Fraunhofer Institute to explore one potential alternative method to current aquatic toxicity testing of chemicals involving the use of fish. This highlights ECHA's commitment to New Approach Methodologies, shaping the future of non-animal testing. 🌱 As experts in chemical toxicity screenings, at ZeClinics we proudly support initiatives like this, showcasing how alternative models are not only feasible but essential for a more ethical, efficient, and sustainable future. Explore our toxicity testing platform 👉 https://lnkd.in/dHKKyKXP 🎧 Check out the Safer Chemicals podcast featuring Sylvia Escher (Fraunhofer) and Tomasz Sobanski (ECHA) to learn more about this groundbreaking initiative. https://lnkd.in/dsfr3DQW Want to know how zebrafish are already reducing animal use in toxicology? Let’s talk. 🚀 #zebrafish #toxicology #chemicaltoxicity

¡Es oficial! 🎉 En solo unos días nuestra empresa hermana, ZeCardio Therapeutics lanzará una campaña de crowdfunding en Capital Cell. Esta es tu oportunidad para formar parte de una revolución en el tratamiento de las enfermedades cardiovasculares. 💓 Nuestros compañeros y compañeras de ZeCardio Therapeutics quieren llevar su molécula innovadora cardioregeneradora a la siguiente fase de desarrollo y ayudar a los corazones dañados a recuperarse. ❤️ ¿Estás listo para apoyar una causa que puede cambiar vidas? ¿Quieres formar parte de esta aventura? Manténte alerta en las redes! #Crowdfunding #RegeneraciónCardíaca #InversiónDeImpacto #InnovaciónEnSalud

This is a quick reminder that our masterclass “From Vision to Strategy! Refine Your Early-Stage Drug Screening” is happening today at 5 PM CET! If you haven’t signed up yet, there’s still time – register here! https://lnkd.in/grrhYFTM

👉 Tomorrow we're hosting the ultimate FREE masterclass on a transformative approach to refine your early-stage drug screening. Trust us, you don't want to miss this. Why Attend This Webinar? This is exclusive content drawn from our extensive experience with our clients. Here's what we'll cover: 1️⃣ How to efficiently screen compounds in vivo in weeks, not months 2️⃣ How to gain actionable insights earlier to optimize hit selection before expensive mammalian testing 3️⃣ How to improve the relevance of preclinical data to clinical outcomes 4️⃣ How to model previously hard-to-study diseases with ease You don’t have to choose between fast, reliable disease-specific models and in-depth functional insights. You can have both — and we’ll show you how. This strategy works ✅ Don’t miss out! Register now here: https://lnkd.in/grrhYFTM

Concerned About the Initial Investment for Novel Models Adoption?  It's natural to be cautious about upfront costs. However, you should consider the significant long-term savings that the right alternative model can bring to your drug discovery process. Investing in the right alternative model is not just an expense; it’s a strategic move that can lead to substantial cost reductions over time. 🔑 Why Invest in Zebrafish Models? Significant Long-Term Cost Savings: Zebrafish can cut preclinical costs by up to 50%, especially for high-throughput drug screenings and lower maintenance costs. Lower Animal Use: By utilizing zebrafish, you can significantly reduce the need for costly mammalian testing in the early stages, leading to decreased expenses on animal care. Accelerated Timelines: With faster reproductive cycles, zebrafish allow you to expedite preclinical timelines, getting your compounds to market faster. Reduced Failure Rates: Zebrafish models provide in vivo fucntional insights early on, helping to lower failure rates in later stages of development, ensuring a more efficient use of your investment. Want to learn more about how zebrafish can optimize your early-stage screening? Join our webinar to discover the advantages! 👉 https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening

Cut Preclinical Costs by 60%: A Game-Changer for Biotech Companies How did we help a biotech company reduce their preclinical trial costs from $1.5 million to just $600,000? 💰 By incorporating zebrafish models into their cardiomyopathy drug development pipeline, they achieved extraordinary results: ⚡ Faster Screening: Compressed the evaluation of 20 compounds into just 7 months, and reduced total validation time (zebrafish + rodents) to 14 months—10 months faster than traditional mammalian models alone. 🧬 Custom Genetic Models: Used CRISPR/Cas9 technology to develop disease-specific models, leading to more relevant insights and better predictions. 💡 Optimized Candidate Selection: Prioritized only the top candidates for rodent testing, improving overall efficiency and reducing clinical attrition rates. Curious about how we did it? Join our upcoming webinar to discover how you can implement similar strategies in your organization! Register Here: https://lnkd.in/grrhYFTM #DrugDiscovery #PreclinicalTrials #ZebrafishModel #BiotechInnovation #Cardiomyopathy #CRISPR #GeneticModels

Reluctant to Change Your Established Models in Drug Discovery? Staying comfortable can be expensive. If your reluctance to change is costing you thousands, how much longer can you afford to stay there? The #DrugDiscovery process is constantly evolving, and sometimes, the changes we fear the most are the ones that can lead to significant improvements. Integrating #zebrafish into your workflow offers a multitude of advantages over traditional models that you won't want to overlook. [ 👀 Look at the comparison below] 🔸Accelerate development time 🔸Reduce costs 🔸Increase success rates in your predictions. Don’t let the fear of change hold you back! Ready to take the step toward more efficient and effective discovery? Join our webinar to learn more about how zebrafish can transform your research. https://lnkd.in/grrhYFTM

Playing it safe with traditional models, unsure if alternatives will pass regulatory scrutiny? In today’s drug discovery landscape, not adopting alternative models is no longer optional; the real question is which one to choose. 🔑 Fact Check: Both #EMA and #FDA are increasingly endorsing alternative models, recognizing the significant utility of #zebrafish, particularly for toxicity and efficacy screenings. Regulators validate the use of zebrafish with these key factors in mind: ✅ Integrated Approaches: The trend is shifting towards integrated strategies where zebrafish play a key intermediary role in screening processes. ✅ Complement, Don’t Replace: Use zebrafish models to generate actionable insights early, enhancing decision-making in the selection of compounds and therapeutic targets. ✅ Aligned with the 3Rs: Zebrafish support the 3Rs principle by minimizing animal use in preclinical testing, providing rapid, scalable results that inform more focused and cost-effective mammalian studies. Don’t overlook this powerful tool! Curious to learn how zebrafish can enhance your preclinical testing? Join our webinar! 👉 https://lnkd.in/grrhYFTM

Exciting news from our sister company, ZeNEUROID! 🚀 ZeNEUROID is expanding its team and looking for talented Bioengineering Neuroscientists to push the boundaries of neuropsychiatric research. If you're passionate about iPSC-derived 3D/4D models and ready to make an impact in cutting-edge neuroscience, this could be your next big opportunity! 🧠🔬 Check out the details and apply below! 👇 #Neuroscience #Hiring #ZeNeuroid #ZeClinics

What do Clemizole, Luxturna, and MEK inhibitors have in common? They were all advanced through zebrafish screenings! These groundbreaking compounds made it to clinical trials—and even the market—thanks to zebrafish models. Think Zebrafish Aren’t Relevant to Human Studies? Think Again! Contrary to popular belief, zebrafish are highly translatable to human. 🔑 Fact Check: Zebrafish share 84% of genes associated with human diseases, and their physiology enables results that are highly applicable to human studies. Zebrafish models have successfully predicted drug efficacy in human clinical trials for >10 compounds, especially in areas where rodent models fall short, including: 🧬 Oncology: Leflunomide (melanoma) & Perphenazine (T cell acute lymphoblastic leukaemia) 🧠 Epilepsy: Clemizole and derivatives 🫀 Congenital Heart Disease: MAPK pathway inhibitors (e.g. vemurafenib or trametinib) 👁️ Retinal Regeneration: Luxturna Gene therapy Curious about real-world zebrafish applications? Join our webinar to explore more! https://lnkd.in/grrhYFTM #DrugDiscovery #Biotech #PharmaInnovation #PreclinicalDevelopment #EarlyStageScreening